Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics VP Ashoo Gupta reported routine equity compensation activity. On March 20, 2026, Gupta exercised restricted stock units (RSUs) into 1,086 shares of common stock at a conversion price of $0.00 per share.
On the same date, 390 common shares were sold at $8.61 per share in an automatic “sell-to-cover” transaction to satisfy tax withholding obligations, as described in the footnotes, rather than a discretionary trade. Following these transactions, Gupta directly held 47,055 common shares, plus RSU awards that continue to vest beginning on June 20, 2025 in scheduled quarterly installments while serving as a company service provider.
4D Molecular Therapeutics describes a late-stage gene therapy pipeline focused on retinal and lung diseases. Lead candidate 4D-150, for wet age-related macular degeneration and diabetic macular edema, is in global Phase 3 trials with RMAT and PRIME designations and strong early data on reducing anti-VEGF injection burden.
The company is also advancing 4D-710 for cystic fibrosis lung disease, showing durable CFTR expression and early clinical activity in the AEROW Phase 1/2 trial, with Phase 2 dosing selected. As of June 30, 2025, non-affiliate equity was valued at $166,461,070, and as of March 16, 2026, 51,051,487 common shares were outstanding, with an additional 16,935,665 shares issuable upon exercise of pre-funded warrants.
4D Molecular Therapeutics reported full year 2025 results and highlighted major partnering and financing activities that support its late-stage gene therapy pipeline. Collaboration and license revenue rose to $85.2 million, mainly from an upfront payment under the Otsuka partnership, while net loss narrowed to $140.1 million from $160.9 million in 2024. Research and development expenses increased to $195.7 million, reflecting advancement of the 4D-150 Phase 3 wet AMD program and other trials. Cash, cash equivalents and marketable securities were $514.0 million as of December 31, 2025, which the company expects will fund its operating plan into the second half of 2028. The company also completed an additional $118 million in equity financings and reported positive interim data and upcoming milestones for 4D-150 in retinal diseases and 4D-710 for cystic fibrosis lung disease.
Novo Holdings A/S reported beneficial ownership of 3,650,737 shares of 4D Molecular Therapeutics common stock, representing 6.4% of the outstanding class as of the event date. Novo Holdings has sole power to vote and dispose of these shares, with no shared voting or dispositive power.
The filing states that the position was not acquired and is not held for the purpose of changing or influencing control of the company, indicating a passive investment intent under the Schedule 13G framework.
4D Molecular Therapeutics, Inc. received an updated Schedule 13G/A from RA Capital Management and related entities reporting a significant ownership stake. As of December 31, 2025, the reporting group beneficially owned 5,713,852 shares of common stock, representing 9.99% of the outstanding shares.
The RA Capital Healthcare Fund directly holds 5,653,211 shares of common stock and pre-funded warrants exercisable for up to 3,610,000 additional shares. These pre-funded warrants include a 9.99% "Beneficial Ownership Blocker," which currently limits exercisability so that beneficial ownership does not exceed 9.99% of the company’s common stock.
RA Capital, along with Peter Kolchinsky and Rajeev Shah, may be deemed beneficial owners through their control and advisory roles, but they expressly disclaim beneficial ownership except for Section 13(d) reporting purposes. The filing also certifies that the securities were not acquired to change or influence control of 4D Molecular Therapeutics.
4D Molecular Therapeutics, Inc. received an updated ownership report from a group of funds affiliated with Biotechnology Value Fund and investor Mark N. Lampert, detailing their passive stake in the company’s common stock.
As of December 31, 2025, the BVF funds and a managed account held Pre-Funded Warrants exercisable for an aggregate of 6,725,665 shares, at an exercise price of $0.0001 per share. A 9.99% ownership cap in these warrants limits how many can be exercised at any time, so only 1,217,992 underlying shares are currently counted as beneficially owned.
Based on the share count referenced from the company’s latest quarterly report and warrant exercises, BVF entities report significant positions: BVF at about 6.1% of outstanding shares, BVF II at about 3.1%, and Trading Fund OS at less than 1%. Aggregating across the complex, BVF Partners, BVF Inc. and Mr. Lampert may each be deemed to beneficially own approximately 9.99% of 4D Molecular’s outstanding common stock. The group certifies that the securities are not held for the purpose of changing or influencing control of the company.
Janus Henderson Group plc reports beneficial ownership of 4,635,875 shares of 4D Molecular Therapeutics common stock, representing 8.1% of the class as of 12/31/2025. The firm has shared power to vote and dispose of all these shares through its investment adviser subsidiaries.
These shares are held in various client accounts, referred to as Managed Portfolios, for which the Janus Henderson asset managers exercise investment and/or voting discretion. Janus Henderson notes that the Managed Portfolios receive all dividends and sale proceeds, and that no single Managed Portfolio owns more than 5% of the company’s common stock.
4D Molecular Therapeutics reported that affiliates of The Goldman Sachs Group, Inc., including Goldman Sachs & Co. LLC, beneficially owned 4,286,077.48 shares of its common stock as of 12/31/2025. This represents 7.5% of the company’s outstanding common shares.
The Goldman Sachs entities report shared voting power over 4,286,060.48 shares and shared dispositive power over 4,286,077.48 shares, with no sole voting or dispositive power. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of 4D Molecular Therapeutics.
4D Molecular Therapeutics entered exchange agreements with RA Capital and Biotechnology Value Fund, under which RA Capital exchanged 4,850,000 common shares and BVF exchanged 1,750,000 common shares for pre-funded warrants to acquire the same number of shares.
As of January 23, 2026, the company had 51,007,874 common shares outstanding, excluding 16,935,665 shares issuable upon exercise of pre-funded warrants outstanding on that date. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share, have no expiration until fully exercised, and are subject to beneficial ownership blockers at 4.99% or 9.99%, as specified in each warrant. The warrants were issued without registration in reliance on the Section 3(a)(9) exemption under the Securities Act.
4D Molecular Therapeutics director Glenn Sblendorio reported a grant of stock options in the company. On January 5, 2026, he received 45,000 stock options to buy common shares at an exercise price of $7.30 per share. These options expire on January 4, 2036.
One-third of the options vest on the first anniversary of January 5, 2026, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Sblendorio beneficially owned 45,000 derivative securities directly.